Interview with the CEO: EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)

Healthcare >> CEO Interviews >> March 30, 2023

Nancy Lurker has been the Chief Executive Officer of Eyepoint Pharmaceuticals Inc. since September 2016. From 2008 to 2015, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc., a Nasdaq-listed health care commercialization company now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held health care information company. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation (Pharmacia), now a part of Pfizer, Inc. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Since April 2018, Ms. Lurker has served as a member of the board of directors of Aquestive Therapeutics (Nasdaq:AQST), a Nasdaq-listed company. Profile

Word count: 2,965

TWST: Tell us about EyePoint’s history, how it’s evolved, and key milestones.

Ms. Lurker: EyePoint is an ophthalmology company focused on

Join for free to read a longer excerpt or purchase this article

Interview with the CEO: EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO: EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS